1AZIZI M, MENARD J, BISSERY A, et al. Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the ATI receptor antagonist valsartan on the angiotensin II-renin feedback interruption [ J]. Am Soc Nephrol , 2004,15(12) :3126-3133.
2AZIZI M, WEBB R, NUSSBERGER J, et al. Renin inhibition with aliskiren : where are we now, and where are we going? [ J ]. Hypertens, 2006,24 ( 2 ) : 243-256.
3WALDMEIER FJ,GLAENZEL U, WIRZ B ,et al. Absorption, distribution, metabolism and elimination of the direct renin inhibitor aliskiren in healthy volunteers [ J/OL] .2007, as doi: 10. 1124/dmd. 106. 013797.
5GRADMAN A H, SCHMIEDER R E, LINS R L, et al. Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients [ J ]. Circulation, 2005, 111 : 1012-1018.
6VILLAMIL A,CHRYSANT S G,CALHOUN D,et al. Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide [ J ]. Hypertens ,2007, 25 ( 1 ) :217-226.
7VAIDYANATHAN S, REYNOLDS C, YEH C M,et al. Phannacokinetics,safety, and tolerability of the novel oral direct rennin inhibitor aliskiren in elderly healthy subjects [ J ]. Clin Pharmacol,2007,47 (4) :453-460.
8VAIDYANATHAN S,WARREN V,YEH C, et al. Pharmacokinetics, safety, and tolerability of the oral Renin inhibitor aliskiren in patients with hepatic impairment[ J ]. Clin Pharmacol,2007, 47(2) :192-200.
9VAIDYANATHAN S, VALENCIA J, KEMP C, et al. Lack of pharmacokinetic interactions of aliskiren, a novel direct renin inhibitor for the treatment of hypertension, with the antihypertensires amlodipine, valsartan, hydrochlorothiazide (HCTZ) and ramipril in healthy volunteers [ J ]. Int J Clin Pract, 2006,60 (11) : 1336-1337.
同被引文献4
1European public assessment report (EPAR) rasilez summary for the public[EB/OL].2009-04.http://www.emea.europa.eu/humandocs/Humans/EPAR/rasilez/rasilez.htm.
2MHRA Drug Safety Update.Aliskiren (Rasilez):risk of angioedema and renal dysfunction[EB/OL].2009,2(10):2-3.http://www.mhra.gov.uk/Publications/Safetyguidance/DrugSafetyUpdate/CON046451.
3EMEA.European Medicines Agency recommends new contraindication and warning for Rasilez and other aliskiren medicines[EB/OL].2009-2-19.http://www.emea.europa.eu/pdfs/human/press/pr/8952309en.pdf.
